 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...154155156157158159160161162163164...208209» |
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody (clinicaltrials.gov) - Apr 28, 2021
P2, N=87, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- SHR-1701 / Jiangsu Hengrui Medicine
[VIRTUAL] Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced solid tumors. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2554;
P1
SHR-1701 showed acceptable safety profile and encouraging antitumor activity in refractory solid tumors, establishing the foundation for further exploration.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Inductive camrelizumab and apatinib for patients with locally advanced and resectable oral squamous cell carcinoma: A single-arm trial (Icemelting trial). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2507;
P1
The chemo-free protocol of induction therapy using Camrelizumab and Apatinib is safe and well-tolerated for the patients with LAOSCC . The MPR rate is much higher using the anti-PD1 and anti-VEGFR protocol than the traditional induction chemotherapy protocol in LAOSCC.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Preliminary results of the efficacy and safety of all-trans retinoic acid combined with low-dose apatinib in the treatment of patients with recurrent/metastatic adenoid cystic carcinoma of the head and neck. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2481;
P2
ATRA combined with low-dose anti-angiogenic drug apatinib could be a potential treatment option for patients with R/M ACC, including those with pretreated advanced ACC after progression on or intolerance to other therapies . These encouraging results were worth further investigations, and a randomized phase 2 trial in ongoing (the Aplus study, NCT04433169).
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2448;
P3
Addition of camrelizumab to GP significantly prolonged PFS as 1L therapy for R/M NPC, with a manageable safety profile . These data suggest that first line treatment with camrelizumab plus GP could be a standard of care for R/M NPC.
- linperlisib (YY-20394) / Shanghai YingLi Pharma
[VIRTUAL] A phase Ib study of a PI3Kδ inhibitor Linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2268;
P1
Toxicities with Linperlisib therapy were generally tolerable and manageable . Further efficacy and safety is being evaluated.
- Ukoniq (umbralisib) / TG Therap, Utuxin (ublituximab) / TG Therap, TG-1701 / TG Therap
[VIRTUAL] Updated results of the selective Bruton tyrosine kinase (BTK) inhibitor TG-1701, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients (pts) with B-cell malignancies. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2262;
P1
The combination of 1701+U2 has been well tolerated and dose escalation continues . The combination shows enhanced depth of response over TG-1701 monotherapy .
- AiRuiKa (camrelizumab) / Incyte, famitinib (SHR 1020) / Jiangsu Hengrui Medicine
[VIRTUAL] Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2062;
P2
Additionally, promising ORR and durable DOR were observed in pts with heavily-treated RCC . These results support further investigation in these settings.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Apatinib in combination with camrelizumab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic acral melanoma. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1844;
P2
The combination of apatinib plus camrelizumab was tolerable and showed promising antitumor activities and PFS improvement in pts with treatment-naïve metastatic acral melanoma . The survival is still in follow up.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS, plinabulin (BPI 2358) / BeyondSpring
[VIRTUAL] A phase I trial of plinabulin in combination with nivolumab and ipilimumab in patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1782;
P1/2
Plinabulin in combination with nivolumab and ipilimumab was safe and well tolerated . A phase 2 study in CPI-experienced patients with relapsed SCLC is planned to confirm the preliminary signals of clinical activity and reduced immune toxicity.
- Irene (pyrotinib) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
[VIRTUAL] Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1671;
P=N/A
Pts in the treatment group received 6 cycles of pyrotinib 400mg + trastuzumab 6mg/kg (LD 8mg/kg) + docetaxel 75mg/m2 + carboplatin (AUC = 6mg/ml·min) (TCbH+Py) treatment while the controlled group received 6 cycles of trastuzumab 6mg/kg (LD 8mg/kg) + docetaxel 75mg/m2 + carboplatin (AUC = 6mg/ml·min) (TCbH) . In this study TCbH+Py neoadjuvant therapy significantly improved the tpCR rate of HER2+ breast cancer pts for about twice higher than TCbH with a manageable safety.
- Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche, plinabulin (BPI 2358) / BeyondSpring
[VIRTUAL] Head-to-head comparison of single agent (SA) plinabulin (Plin) versus pegfilgrastim (Peg) for the prevention of chemotherapy-induced neutropenia (CIN) in the phase 3 trial PROTECTIVE-1. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1645;
P3
SA Plin has efficacy for Doc CIN prevention non-inferior compared to SoC Peg, and accordingly has comparable (or numerically better) profile for clinical sequelae of CIN . Plin has an advantage for bone pain, platelet counts, convenience of use (same day vs next day dosing) over SoC Peg and has anticancer activity.
- Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche, plinabulin (BPI 2358) / BeyondSpring
[VIRTUAL] Chemotherapy induced profound neutropenia (PN) in patients (pt) with breast cancer (BC) after chemotherapy and plinabulin (Plin) plus pegfilgrastim (Peg) combination versus (vs) peg alone: Final phase 3 results from protective-2 (BPI-2358-106). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1644;
P3
In conclusion, Peg still cannot protect patients with the most severe form of neutropenia, PN, at 46.4% in this study . Adding Plin to Peg offers superior protection for the prevention of profound neutropenia by reducing > 50% of PN, and its clinical sequelae in FN and hospitalization as compared to Peg alone.
- Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche, plinabulin (BPI 2358) / BeyondSpring
[VIRTUAL] Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1631;
P3
Adding Plin to Peg offers superior CIN protection compared to Peg alone and also has a superior safety profile by lowering over 20% of grade 4 AE . The effect size of the CIN protection in the combination is also correlated to clinical meaningful FN reduction compared to peg alone.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab combined with ablation and chemotherapy for pancreatic cancer with liver metastases: A single-arm, phase Ⅱ, prospective clinical study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1581;
P=N/A
Secondary endpoints are objective response rate, disease control rate, progression-free survival, overall survival and safety . On the basis of a threshold 6-month PFS rate of 25%, targeting an expected 6-month PFS rate of 44% and assuming 18 months follow-up, 80% power and a one-sided α = 0.05, this design requires 34 evaluable patients to be accrued over 2 years.
- AiTan (rivoceranib) / HLB Bio Group, Avastin (bevacizumab) / Roche, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab plus apatinib combined with TACE and cryoablation in the first-line treatment of advanced hepatocellular carcinoma. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1572;
The IMbrave 50 trial has reported the successful efficacy of atezolizumab and bevacizumab combination therapy in advanced hepatocellular carcinoma, which indicate the potential efficacy of combination of immunotherapy and antiangiogenesis therapy in HCC patients...TACE was administrated at the first treatment cycles on day 1or 2, the chemotherapy regimens included 100-150mg oxaliplatin, 750-1000mg fluorouracil, or 30-50 mg lobaplatin, raltitrexed 2-4mg, and epirubicin 40-80 mg...TACE and cryoablation was given as combination therapy and the periods were assessed by the investigator . The primary endpoint is objective response rate (complete or partial response according to mRECIST) and Progression-Free-Survival (Time ranges from random to the first occurrence of disease progression or death from any cause).
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase Ⅱ study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1494;
P2
The primary endpoint is objective response rate (complete or partial response according to mRECIST) and Progression-Free-Survival (Time ranges from random to the first occurrence of disease progression or death from any cause). This study preliminarily demonstrated that the perioperative treatment of camrelizumab combined with apatinib improved the MPR and pCR with managable safety in intermediate/advanced resectable HCC.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1488;
P2
This study preliminarily demonstrated that the perioperative treatment of camrelizumab combined with apatinib improved the MPR and pCR with managable safety in intermediate/advanced resectable HCC. Long-term follow-up of C+A demonstrated remarkable survival benefit in advanced HCC pts, which further suggested that C+A is a promising combination therapy in advanced HCC pts.
- AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] A prospective, phase II, single-arm study of neoadjuvant/conversion therapy with camrelizumab, apatinib, S-1 ± oxaliplatin for locally advanced cT4a/bN+ gastric cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1473;
P2
Combination of camrelizumab, apatinib, S-1 ± oxaliplatin is feasible, safe, and efficient in neoadjuvant/conversion therapy for cT4a/bN+ GC . It may remodel immune microenvironments and induce anti-tumor immune responses.
- AiRuiKa (camrelizumab) / Incyte, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] A phase II study of neoadjuvant immunotherapy combined with chemotherapy (camrelizumab plus albumin paclitaxel and carboplatin) in resectable thoracic esophageal squamous cell cancer (NICE study): Interim results. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1472;
A phase III randomized controlled trial is required to demonstarate the possible survival improvement . Trial registration: ChiCTR1900026240
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Apatinib in combination with docetaxel and S1 chemotherapy in the first-line treatment of metastatic gastric cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1468;
P2
Adding apatinib to standard DS chemotherapy as the first line treatment would be well tolerant in patients with metastatic gastric cancer, the spectrum of toxicity were not exceeding expectation . This modality also exhibits prolonged PFS, which might provide an alternative therapeutic strategy for metastatic gastric cancer.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1460;
A regiment of 2–4 cycles of neoadjuvant camrelizumab (200 mg, intravenous, day 1), nab-paclitaxel (150 mg/m2, intravenous, day 1), nedaplatin (50 mg/m2, intravenous, day 1), and apatinib (250 mg, orally, day 2–4) was given to the treatment-naive patients with resectable locally advanced ESCC . Neoadjuvant camrelizumab combined with chemotherapy plus apatinib is a safe and tolerable treatment for patients with locally advanced ESCC, and the MPR and pCR rate are promising.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab combined with FLOFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: Updated results of efficacy and safety. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1450;
P2
Camrelizumab combined with FOLFOX was an effective and safe neoadjuvant therapy strategy for patients with resectable locally advanced GC/GEJC . Furthermore, the analysis of biomarkers with clinical benefits is undergoing.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1442;
P2
In this NIC-ESCC2019 phase 2 study, histologically or cytologically confirmed ESCC pts (stage II-IVA) were enrolled to receive two cycles of neoadjuvant chemoimmunotherapy (NIC) with camrelizumab (200 mg on day 1) plus nab-paclitaxel (260 mg/m² in total on day 1 and day 8) and cisplatin (75 mg/m² in total on days 1-3) of each 21-day cycle, followed by esophagectomy . The addition of camrelizumab to neoadjuvant chemotherapy in ESCC demonstrated promising efficacy with acceptable toxicity, supporting the further investigation in a randomized phase 3 clinical trial.
- AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC). () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1407;
P3
Camrelizumab in combination with paclitaxel and cisplatin has the potential to become a new standard first-line therapy in patients with advanced or metastatic ESCC . Based on this trial, we are submitting NDA to seek the approval from China National Medical Products Administration for camrelizumab plus chemotherapy in the treatment of untreated advanced or metastatic ESCC.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Apatinib plus vinorelbine versus vinorelbine for advanced triple-negative breast cancer with failed first or second-line treatment: The NAN trial. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1370;
P2
Collectively, among patients with advanced TNBC with failed first/second-line treatment, apatinib plus vinorelbine show a promising benefit in PFS compared to vinorelbine monotherapy . Apatinib plus vinorelbine regimen shows promising efficacy and manageable toxicity, which might be a previously unappreciated therapeutic option for advanced TNBC.
- Irene (pyrotinib) / Jiangsu Hengrui Medicine
[VIRTUAL] Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1332;
P2
Small molecule tyrosine kinase inhibitor (TKI) with enhanced penetrability to the blood brain barrier combined with capecitabine have demonstrated promising clinical outcomes in HER2-positive metastatic BC patients with untreated (such as lapatinib) or previously treated (such as neratinib) BM . Pyrotinib plus capecitabine resulted as an effective and safe treatment for HER2-positive BC patients with radiotherapy-naive BM, but the efficacy was modest in those with radiotherapy-treated BM.
- dalpiciclib (SHR6390) / Jiangsu Hengrui Medicine, Irene (pyrotinib) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
[VIRTUAL] Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1330;
P1/2
Data from phase Ib showed the triplet combination of pyrotinib, letrozole, and SHR6390 had an acceptable safety profile and encouraging preliminary efficacy, potentially offering a chemotherapy sparing treatment option for patients with HR+/HER2+ MBC . Enrollment on phase II is ongoing.
- AiRuiKa (camrelizumab) / Incyte, famitinib (SHR 1020) / Jiangsu Hengrui Medicine, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1301;
P2
Addition of famitinib to camrelizumab and nab-paclitaxel showed promising antitumour activity as first-line therapy with manageable toxicity profile for IM subtype advanced TNBC patients . Results from ongoing randomized controlled trial FUTURE-SUPER (NCT 04395989) are eagerly awaited.
- dalpiciclib (SHR6390) / Jiangsu Hengrui Medicine
[VIRTUAL] Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1292;
P3
The study met its primary endpoint, demonstrating that dalpiciclib plus fulvestrant significantly improved PFS versus placebo plus fulvestrant, with a manageable safety profile . Our findings support dalpiciclib plus fulvestrant as a new treatment option in pts with HR+/HER2- ABC who relapsed or progressed on endocrine therapy.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab monotherapy or in combination with apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A multicenter, open-label, single-arm, phase II study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1104;
The secondary endpoints are progression-free survival (PFS), overall survival (OS), disease control rate (DCR), time to objective response (TTR), duration of response (DOR) and safety . This study is ongoing.
- SHR-1701 / Jiangsu Hengrui Medicine
[VIRTUAL] SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for advanced NSCLC with EGFR mutations: Data from a multicenter phase 1 study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1032;
P1
SHR-1701 monotherapy shows a manageable safety profile and encouraging antitumor activity in advanced EGFR+ NSCLC pts after failure of at least 1L standard EGFR TKI . Further investigation of SHR-1701 combination therapy for EGFR+ NSCLC is warranted.
- AiTan (rivoceranib) / HLB Bio Group, Irene (pyrotinib) / Jiangsu Hengrui Medicine
[VIRTUAL] Efficacy and safety of pan-ErbB inhibitor pyrotinib combined with antiangiogenic agent apatinib for HER2-mutant or amplified metastatic NSCLC: A phase II clinical study. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_1012;
Further investigation of SHR-1701 combination therapy for EGFR+ NSCLC is warranted. Pyrotinib combined with apatinib showed potent anti-tumor activity and acceptable safety profile in metastatic NSCLC with HER2 amplification or activating mutations.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte, HTI-1090 / Jiangsu Hengrui Medicine
[VIRTUAL] A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_908;
P1
SHR9146 plus camrelizumab in combination with/without apatinib demonstrated promising anti-tumor activity with acceptable safety in pts with advanced solid tumors . Further study is needed to validate the efficacy and safety.
- linperlisib (YY-20394) / Shanghai YingLi Pharma
[VIRTUAL] A phase Ib study of the PI3Kδ inhibitor linperlisib in patients with advanced solid tumors. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_906;
P1
Monotherapy treatment with linperlisib was observed to impart a high DCR in advanced solid cancers of many types . Available data from linperlisib and other PI3K inhibitors suggests that linperlisib may limit tumor growth directly, but also by affecting the tumor immune microenvironment .
- | AiRuiKa (camrelizumab) / Incyte
Journal, PD(L)-1 Biomarker, IO biomarker: N-glycosylation of PD-1 promotes binding of camrelizumab. (Pubmed Central) - Apr 28, 2021
Glycosylation of asparagine 58 (N58) promotes the interaction with camrelizumab, while the efficiency of camrelizumab to inhibit the binding of PD-L1 is substantially reduced for glycosylation-deficient PD-1. These results increase our understanding of how glycosylation affects the activity of PD-1-specific MAbs during immune checkpoint therapy.
- || Irene (pyrotinib) / Jiangsu Hengrui Medicine, Herceptin (trastuzumab) / Roche
Clinical, Journal: Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab. (Pubmed Central) - Apr 28, 2021
The patient had a stable disease time of more than four months. Our case provides evidence for the feasibility and efficacy of pyrotinib with carboplatin in treating patients with HER2-positive relapsed or metastatic breast cancer who may develop resistance to trastuzumab.
- || SHR-1819 / Jiangsu Hengrui Pharma
Enrollment open: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects (clinicaltrials.gov) - Apr 27, 2021
P1, N=42, Recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Our case provides evidence for the feasibility and efficacy of pyrotinib with carboplatin in treating patients with HER2-positive relapsed or metastatic breast cancer who may develop resistance to trastuzumab. Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial: Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach (clinicaltrials.gov) - Apr 27, 2021
P2, N=41, Recruiting, Sponsor: Peking University
- || HRS4800 / Jiangsu Hengrui Pharma
New P1 trial: A Trial to Evaluate the Safety and PK Profile of HRS4800 in Healthy Subjects (clinicaltrials.gov) - Apr 27, 2021
P1, N=50, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal, PARP Biomarker: Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC. (Pubmed Central) - Apr 27, 2021
Moreover, apatinib repressed LC3A, Beclin‑1, p‑AKT expression levels and promoted the cell apoptosis rate in A549/DTX cells and docetaxel‑treated A549/DTX cells. In conclusion, apatinib synergize the effect of docetaxel in treating patients with advanced NSCLC and chemoresistant NSCLC cells via inhibiting autophagy.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 27, 2021
P=N/A, N=290, Recruiting, Sponsor: Shanghai Zhongshan Hospital
In conclusion, apatinib synergize the effect of docetaxel in treating patients with advanced NSCLC and chemoresistant NSCLC cells via inhibiting autophagy. Not yet recruiting --> Recruiting | N=514 --> 290 | Trial completion date: Dec 2024 --> Mar 2026 | Initiation date: Aug 2020 --> Mar 2021 | Trial primary completion date: Aug 2024 --> Mar 2024
- |||| noiiglutide (SHR20004) / Jiangsu Hengrui Pharma
Enrollment open: The Effect of SHR20004?Noiiglutide ? on Body Weight in Obese Subjects Without Diabetes (clinicaltrials.gov) - Apr 27, 2021
P2, N=252, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting | N=514 --> 290 | Trial completion date: Dec 2024 --> Mar 2026 | Initiation date: Aug 2020 --> Mar 2021 | Trial primary completion date: Aug 2024 --> Mar 2024 Not yet recruiting --> Recruiting
- |||||| Aidixi (disitamab vedotin) / Pfizer
Enrollment open: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression (clinicaltrials.gov) - Apr 27, 2021
P3, N=351, Recruiting, Sponsor: RemeGen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Apr 26, 2021
P2, N=155, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- | Ibrance (palbociclib) / Pfizer, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer (clinicaltrials.gov) - Apr 25, 2021
P2, N=57, Not yet recruiting, Sponsor: Guangdong Provincial People's Hospital
- | SHR-A1811 / Jiangsu Hengrui Medicine
SHR-A1811 seems like an anti-HER2 ADC (Twitter) - Apr 25, 2021
- || Irene (pyrotinib) / Jiangsu Hengrui Medicine
Clinical, Journal, HEOR, Real-world evidence, IO biomarker: HER2 transmembrane domain mutation: comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma. (Pubmed Central) - Apr 24, 2021
Targeted therapy is the dominant choice for patients harboring this targetable mutation and longer OS could possibly be achieved through rechallenge with TKI of stronger binding affinity. Response to fifth-line pyrotinib was observed.
- |||||||||| retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
New P2/3 trial: SHR-1701-III-301: A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC (clinicaltrials.gov) - Apr 23, 2021
P2/3, N=439, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- |||| retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
New P1/2 trial: SHR-1701-II-207: Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors (clinicaltrials.gov) - Apr 23, 2021
P1/2, N=113, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.